BRAF and colorectal cancer: In addition to BRAF mutations, BRAF selective amplification was found to be the mechanism of acquired MEK inhibitor resistance by two groups in a colorectal cancer cell line in vitro [77,80], with MEK hyperactivation being observed in these resistant cells.